ALTSTATION.IO

IQVIA Holdings Inc. (IQV) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$186.06

Change

+2.82%

Market Cap

$31.69B

Avg Volume

1.4M

Company Overview

IQVIA Holdings Inc. is a leading provider of clinical research services and healthcare analytics to the life sciences sector. Headquartered in Durham, North Carolina, the company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. They offer cloud-based applications, real-world evidence generation, clinical trial support, and various consulting services. Their clients include pharmaceutical companies, biotechnology firms, medical device manufacturers, and consumer health organizations.

IQVIA holds a strong position in the healthcare analytics and clinical research market, often seen as a market leader due to its comprehensive service offerings and extensive data capabilities. They leverage advanced analytics and a vast database of healthcare information to deliver insights that inform decision-making and improve patient outcomes. Key competitors include ICON plc and PRA Health Sciences, which also focus on clinical trial management and research. The competitive landscape is dynamic, with ongoing pressure to innovate and adapt to changes in regulatory environments and technological advancements, such as AI in drug development.

Currently, IQVIA is in a growth phase, driven by increased demand for their clinical research and analytics services. The company’s strategic partnership with Sarah Cannon Research Institute highlights its commitment to enhancing clinical trial efficiency. Recent financial results show a strong revenue increase, with an annual growth rate of around 9% in recent quarters. This momentum indicates that IQVIA is well-positioned to capitalize on the evolving needs of the healthcare sector.

Key Financials

Market Cap

$31.69B

Revenue

$16.31B

EBITDA

$3.43B

Gross Margin

33.3%

Profit Margin

8.3%

Revenue Growth

10.3%

Total Cash

$2.14B

Total Debt

$15.95B

Free Cash Flow

$2.21B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

23.73

Forward P/E

13.13

Beta

N/A

52-Week High

$247.05

52-Week Low

$134.65

EPS

$7.84

50-Day Avg

$228.93

200-Day Avg

$191.69

Price/Book

4.85

Technical Analysis

Over the past 52 weeks, IQVIA Holdings Inc. (IQV) has exhibited a bearish trend, declining approximately 9.4% from its peak. The stock previously reached a high of around $220 in February before beginning a steady descent. Key support is evident at the $180 level, while resistance can be observed around $187.49, which aligns with the price level seen recently. The chart also highlights a notable descending channel formation, suggesting bearish sentiment. In recent weeks, momentum has weakened, evidenced by the sharp drop following a failure to break above resistance. Currently, the price of $186.06 sits just above its 52-week support, implying cautious sentiment among traders as the stock approaches a critical juncture.

Recent News and Developments

Here’s a summary of the latest news and developments for IQVIA Holdings Inc

(IQV) stock in the past week:

1. IQVIA Beats Q4 Revenue and Earnings, but 2026 Profit Outlook Disappoints

IQVIA Holdings Inc. reported strong financial results for the fourth quarter and full year 2025, exceeding analyst expectations for both revenue and adjusted earnings per share (EPS). The company’s fourth-quarter revenue reached $4.36 billion, a 10.3% year-over-year increase, and adjusted EPS hit $3.42, surpassing forecasts. Despite this strong performance, IQVIA’s 2026 profit forecast fell below Wall Street estimates, primarily due to projections of higher interest expenses.

2. Analyst Price Target Reductions Amidst AI Concerns and Higher Interest Expenses

BMO Capital and Evercore ISI both lowered their price targets for IQVIA stock, even while maintaining “Outperform” ratings. BMO Capital reduced its target to $250 from $260, citing concerns about artificial intelligence as a potential competitive threat and a softer 2026 revenue outlook for its Research & Development Solutions (R&DS) segment. Similarly, Evercore ISI decreased its target to $225 from $250, reflecting higher interest expense projections and investor worries regarding AI’s impact, despite suggesting that operating trends are stabilizing.

Market Sentiment and Analyst Recommendations

Bull Case

IQVIA just posted 10.3% revenue growth and beat Q4 earnings handily, proving the core business still works. The R&D Solutions segment is firing on all cylinders with a 1.18 net book-to-bill ratio, signaling strong demand recovery in biotech funding. At 23.73x P/E, the stock is trading at a discount to historical averages for a company of this quality and growth profile. Analysts have a consensus target of $252.10, implying 35% upside from current levels at $186.06. The segment reorganization effective January 2026 shows management is optimizing operations to capture margin expansion. AI integration across clinical and commercial workflows is a real competitive moat, not a threat if executed properly. The stock is oversold at current levels with RSI in oversold territory and support holding at $180, creating a compelling risk-reward for patient buyers.

Bear Case

The 21% weekly plunge and 9.4% decline from 52-week highs reveal real investor concern that isn’t just noise. Management’s 2026 profit guidance missed expectations specifically due to higher interest expenses, and with $15.95B in debt against only $2.14B in cash, the balance sheet is stretched. The net debt-to-EBITDA ratio is elevated, limiting financial flexibility and making the company vulnerable to further rate pressures. AI is legitimately a competitive threat to IQVIA’s high-margin R&D Solutions business, and two major analysts (BMO and Evercore) both cut targets citing AI concerns. The R&DS segment itself faces a softer outlook according to BMO, which is IQVIA’s crown jewel. The stock is testing critical support at $180, and a break below that level could trigger another leg down given the bearish channel formation. Valuation compression is justified until the company proves it can offset AI disruption with margin defense.

What to Watch

Monitor 2026 revenue guidance for the R&D Solutions segment specifically at the next quarterly earnings call. The net book-to-bill ratio of 1.18 is strong, but watch if that momentum sustains or rolls over as a leading indicator of biotech spending trends. Track quarterly interest expense levels and any debt reduction announcements, as higher rates are actively pressuring profitability. Watch for quarterly gross margin trends in the Technology & Analytics Solutions (soon to be renamed Commercial Solutions) segment to see if the reorganization drives operational efficiency. The stock needs to hold $180 support; a break below signals institutional capitulation and could warrant reassessing the bull thesis. Monitor competitive announcements from rivals using AI in clinical trial management and real-world data analytics. Earnings calls should reveal management commentary on AI’s actual impact on win rates and pricing power, which will determine if this sell-off is overblown or justified.

Analyst Consensus

BUY

Based on 20 analyst opinions

Low Target

$210.00

Mean Target

$252.10

High Target

$290.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

N/A

Earnings & Dividends

Next Earnings

May 06, 2026

EPS (Trailing)

$7.84

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is IQV a good stock to buy?

Yes, analysts recommend buying IQV with a target price of $252.10. Given its current price of $186.06, there’s significant upside potential.

What is IQV’s price target?

The analyst consensus price target for IQV is $252.10. This represents an upside of about 35.4% from its current price.

Does IQV pay a dividend?

No, IQV does not pay a dividend. The focus is on growth rather than returning cash to shareholders.

What is IQV’s P/E ratio?

IQV’s current P/E ratio is 23.73, while the forward P/E is 13.13. This suggests that the stock may be undervalued based on future earnings growth expectations.

What is the 52-week range for IQV?

IQV’s stock has traded between $134.65 and $247.05 over the past year. This wide range indicates volatility but also opportunities for investors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.